Clinical trial Recruiting at 1 site Observational Ages 18 to 70

Understanding growth hormone deficiency after a brain injury in adults

Official title: Characterizing Growth Hormone Deficiency in Traumatic Brain Injury: Evaluation of the Growth Hormone in Adult Quality of Life Questionnaire

Run by University of Calgary · NCT07795736 · Data updated 2026-11-12

This observational study tests whether growth hormone deficiency affects quality of life and symptoms in adults with traumatic brain injury and whether GH replacement helps after 12 weeks.

More Traumatic Brain Injury trials

Quick facts

Study typeObservational
Ages18 Years to 70 Years
SexAll
Enrollment200 (estimated)
SponsorUniversity of Calgary
Academic / other
Locations2 sites (Calgary, Alberta and 1 other locations)
StatusRecruiting
StartedJune 1, 2024
Main results expectedMarch 1, 2028
Study endsNovember 1, 2028
Registry record updatedAugust 31, 2026
Trial IDNCT07795736 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults 18-75 with a diagnosed mild TBI, at least 1 year of persistent symptoms, fluent in English, and referred for suspected GHD.

Probably not a fit

Patients without growth hormone deficiency or those not receiving GH replacement will not experience treatment-related benefits.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study observes adults with mild to moderate/severe traumatic brain injury to see how growth hormone deficiency relates to quality of life, fatigue, mood, and sleep. Participants complete baseline questionnaires and undergo provocative testing for GHD. If GHD is diagnosed, some may receive growth hormone replacement and be followed for 12 weeks to assess change in symptoms and quality of life. The study also explores whether a QoL-AGHDA score can help predict GHD and measure treatment response. No experimental interventions are required other than standard clinical testing and observational follow-up.

Why it matters

Potential benefit: If successful, the study could help identify GHD more accurately in brain-injured patients and show whether GH replacement improves symptoms and quality of life.

How similar studies have gone: Prior research has shown that GHD can occur after TBI and that GH testing is variable; this study builds on mixed evidence and is exploratory in nature.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion criteria: Adults aged 18-70 years must be referred and have a diagnosis of mTBI made by a brain injury specialist physician and meet the 2023 ACRM diagnostic criteria (Appendix A, Panel A) or the NIH diagnostic criteria for moderate/severe TBI (Appendix A, Panel B). All participants must be symptomatic for at least one-year post-injury (determined by the Glasgow Extended Scale score of less than 8 for moderate/severe TBI and a Rivermead Post-Concussion Questionnaire score of \> 13 with 3 or more symptoms scored \> 3 for mTBI), at the time of screening. All participants must also be fluent in English and be able to either complete questionnaires online or over the phone.

In terms of concomitant therapies and medication, all prescription and non-prescription medications (e.g., over-the-counter drugs and herbal supplements) and therapies will be recorded by participants during baseline assessments. Participants with GHD on treatment will be asked to disclose any changes in medications/and or therapies at each bi-weekly follow up questionnaires.

Exclusion criteria include untreated pituitary deficits to minimize confounding factors (unless treated/consulted with Dr. Debert and/or Dr. Lithgow), other intracranial abnormalities, chronic neurological conditions, untreated medical conditions, major medical conditions in the past 6 months such as stroke, and current or planned pregnancy.

Where it's running

  • University of Calgary
    Calgary, Alberta, Canada
    Recruiting
  • Foothills Medical Center, Main Floor Special Services
    Calgary, Alberta, Canada
    Not yet recruiting

Study contacts

  • Principal investigator: Chantel T Debert, MD MSc FRCPC CSCN — University of Calgary
  • Study coordinator: Chantel T Debert, MD MSc FRCPC CSCN
  • Email: cdebert@ucalgary.ca
  • Phone: (403) 944-4500

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.